|
 |
IressaThis page contains recent news articles, when available, and an overview of Iressa but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.The author forecasts AstraZeneca's Iressa (gefitinib) will overcome its disappointing start in the NSCLC arena following positive results of two recent ... Earthtimes (press release) New Agent for Some Drug-Resistant Non-Small Cell Lung Cancers - Dec 23, 2009 Over time, however, the tumor cells develop additional abnormalities in EGFR, enabling them to recommence their growth, even in the presence of Iressa or ... Science Daily (press release) Compound May Fight Hard-to-Treat Lung Cancer - Dec 29, 2009 The scientists say non-small cell lung cancers that had become invulnerable to the chemotherapy drugs Iressa and Tarceva were stymied in a study by a ... WebMD Clarient Buys Applied Genomics to Pave Way to EGFR Testing Market for NSCLC - Dec 23, 2009 The company also inked a deal with Iressa-maker AstraZeneca to commercialize an RT-PCR-based EGFR29 mutation kit in Europe as a companion diagnostic for the ... GenomeWeb Daily News Targeted Agent Tops Chemo for Selected NSCLC - Dec 21, 2009 Lung cancer patients selected by mutation status had a 50% improvement in progression-free survival (PFS) when treated with gefitinib (Iressa) compared with ... MedPage Today Reportlinker Adds Lung Cancer Therapeutics Market Outlook and Pipeline Analysis - Dec 17, 2009 Arrowhead forecasts AstraZeneca's Iressa (gefitinib) will overcome its disappointing start in the NSCLC arena following positive results of two recent Phase ... PR Newswire (press release) Surveyed European Oncologists Cite Cost Most Frequently as the Factor ... - Dec 17, 2009 While Avastin, Tarceva and Iressa have shown modest efficacy in select patient populations, other agents in late-stage development have struggled to reach ... PR Newswire (press release) More meds in the state-subsidized basket - Dec 23, 2009 Alimta and Iressa, to treat 953 lung cancer patients, will also be added. The drugs Herceptin and Tykerb, for the treatment of metastatic breast cancer in ... Ha'aretz UM: Health - Dec 17, 2009 ...research has changed the way lung cancer is treated: “Drugs like Iressa [a lung cancer drug] should only be given to people with certain mutations. ... The Ann Arbor Chronicle The Top 10 Medical Advances of the Decade - Dec 17, 2009 ..."Drugs like Iressa [a lung cancer drug] should only be given to people with certain mutations," Burmeister said. "This is really only the start, ... ABC News Research: Compound found to halt common type of drug-resistant lung cancer - Dec 29, 2009 According to the researchers, they were able to thwart non-small cell lung cancers that seemed to have become invulnerable to the drugs Iressa and Tarceva ... HealthJockey.com Scientists Map Cancer Genes; Personalized Treatments Could Be Next - Dec 18, 2009 Drugs such as Roche's (RHHBY) Herceptin and AstraZeneca's (AZN) Iressa also target tumor cells that carry specific mutations. Utilizing the new research ... Daily Finance The Changing Face of Medicine, 1984-2009: - Dec 29, 2009 Erlotinib (Tarceva) and gefitinib (Iressa) also appeared on the market, but it wasn't until about 2004 that researchers began to figure out why these two ... MedPage Today Anti-smoking drugs in health basket - Dec 23, 2009 Among the new medications or drugs already in the basket with new indications are Erbitux, Iressa, Afinitor, Sutent, Nexavar, Temodal, Torisel, Gemzar, ... Jerusalem Post Cancer du poumon : de nouvelles molécules prometteuses - Dec 23, 2009 Les chercheurs espèrent que ces molécules seront cliniquement plus efficaces et mieux tolérées que les inhibiteurs actuels, comme l'Iressa et le Tarceva. ... AFP Υγεία: ΦάÏ?μακο κατά του καÏ?κίνου του πνεÏ?μονα - Dec 27, 2009 ΥπάÏ?χουν φάÏ?μακα Ï€Ï?ώτης γÏ?αμμής τα οποία καταστÎλλουν τη δÏ?άση του υποδοχÎα, αυτά είναι το Iressa (γεφιτινίµπη) και το Tarceva (εÏ?λοτινίμπη). ... Sportime å?¯ä»¥å°?抗難治型肺癌的æˆ?分 - Dec 31, 2009 ...科å¸å®¶å€‘表示，å°?化療藥物Iressaå’ŒTarceva變得無作用的é?žå°?細胞肺癌，會被é?”é‚£-法æŸ?實驗室è¨è¨ˆé…?方的一個æˆ?分影響。 ç ”ç©¶è€…è¡¨ç¤ºï¼Œä»–å€‘çš„æ–°æˆ?ä»½é¡¯ç¤ºå‡ºè‚ºç™Œç ”ç©¶èˆ‡ç™¼å±•çš„ ... 臺灣新浪網 Starter storstilt gentesting av lungekreftsyke - Dec 15, 2009 Legemiddelet Iressa har bare effekt pÃ¥ en gruppe pasienter, som utgjør om lag 10 prosent av lungekreftsyke i Norge. Men for disse alvorlig syke personene ... Dagbladet.no ЛекарÑ?тво от рака лёгких уÑ?пешно теÑ?тируетÑ?Ñ? на мышах - Dec 28, 2009 ЛекарÑ?тва прÑ?мого дейÑ?твиÑ? длÑ? лечениÑ? немелкоклеточного рака лёгких называютÑ?Ñ? Iressa и Tarceva. Они предназначены длÑ? блокированиÑ? «переключениÑ?», ... медицинский портал Здоровье Украины Noi molecule eficiente în combaterea cancerului pulmonar, descoperite de ... - Dec 24, 2009 Cercetătorii americani speră că aceste molecule vor fi mai eficiente ÅŸi mai bine tolerate decât actuala grupă de inhibitori, din care fac parte Iressa ÅŸi ... Monitorul de Suceava æ–°ã?—ã?„肺ã?Œã‚“治療薬ã?®å?¯èƒ½æ€§ã€?ç±³ç ”ç©¶å ±å‘Š - Dec 23, 2009 ...通常ã€?ã?“ã?®é?ºä¼?å?ã?®å¤‰ç•°ã‚’防ã??効能をæŒ?ã?¤ã‚¤ãƒ¬ãƒƒã‚µï¼ˆIressa）やタルセãƒ?（Tarceva）ã?ªã?©ã?®æ²»ç™‚è–¬ã?Œç”¨ã?„られるã?Œã€?二次的ã?ªé?ºä¼?å?変異ã?Œèµ·ã??ã?¦è…«ç˜?ã?Œè–¬å‰¤è€?性をæŒ?ã?¤ã?“ã?¨ ... AFPBB News 美 새로운 í??ì•” 치료약ì?˜ 가능성 발견! - Dec 23, 2009 ...보통 ì?´ ìœ ì „ìž? ë³€ì?´ë¥¼ 막는 기능ì?„ 가진 ì?´ë ˆì‚¬(Iressa)와 타세바(Tarceva) 등ì?˜ 치료약ì?´ ì?´ìš©ë?˜ì§€ë§Œ ì?´ì°¨ì ?ì?¸ ìœ ì „ìž? ë³€ì?´ê°€ ì?¼ì–´ë‚œ 종양ì?´ ì•½ì œ 내성ì?„ 지니는 ... AFPBB NEWS Mapas genéticos vão transformar a luta contra o câncer - Dec 16, 2009 Medicamentos como o Herceptin (Roche) e Iressa (Astra-Zeneca) também atacam células com mutações especÃficas. Stratton disse que o objetivo agora é produzir ... O Globo Nadzieja dla chorych na raka pÅ‚uc - Dec 23, 2009 ...przez nich inhibitor okaże siÄ™ bardziej skuteczny i lepiej tolerowany niż dotychczas stosowane inhibitory EGFR dostÄ™pne pod nazwami Iressa i Tarceva. ... PAP Erst Gentest, dann Therapie - Dec 26, 2009 EGFR-Molekül lässt sich mit den Wirkstoffen Gefitinib (vermarktet als „Iressa“) und Erlotinib („Tarceva“) für eine gewisse Zeit blockieren. ... Tagesspiegel Krebs: Häufige Hautinfektionen nach EGFR-Inhibitoren - Dec 10, 2009 ...die den EGFR blockieren, aber auch Gefitinib (Iressa®) und Erlotinib (Tarceva®), welche die Weiterleitung der Wachstumssignale in der Krebszelle hemmen. ... Deutsches Ärzteblatt El ADN de dos cánceres se descifra - Dec 17, 2009 Medicamentos como Herceptin de Roche AG e Iressa de AstraZeneca también apuntan a células con mutaciones. “Lo que estamos viendo hoy va a transformar la ... El Comercio (Ecuador) FDA Allows Unapproved Drugs To Stay On the Market - Oct 27, 2009 Iressa (AstraZeneca) for lung cancer was approved by the FDA in 2003 after it was found to reduce the size of the tumor. Later studies found it did not ... InjuryBoard.com (blog) Agenda: Astra Zeneca Feeling Some Pain - Oct 28, 2009 The story is reminiscent of Iressa, prompting analysts at Collins Stewart to highlight their concerns over AZ's replacement power for ... Wall Street Journal (blog) Drugs join forces to overcome lung cancer resistance - Oct 30, 2009 The research focused on a vexing problem: targeted therapies like Iressa and Tarceva are very effective for lung cancer patients whose tumors have certain ... Vanderbilt University News Neoadjuvant Taxotere® and ADT Well Tolerated in High-risk Prostate Cancer - Oct 27, 2009 Researchers from the Virginia Mason Medical Center in Seattle, Washington, have also reported that neoadjuvant Taxotere and Iressa® (gefitinib) is well ... Cancer Consultants Report Highlights Cancer Advances - Nov 9, 2009 Another targeted agent, gefitinib (Iressa), did not improve survival compared with methotrexate in patients with recurrent squamous-cell carcinoma of the ... MedPage Today Unproven Drugs Allowed to Remain on Market By FDA - Nov 2, 2009 The FDA approved AstraZeneca's lung cancer drug Iressa in 2003 based on early results showing it reduced the size of tumors. But later studies showed the ... InjuryBoard.com (blog) NCI Seeking Participants for New Mesothelioma Drug Trial - Oct 19, 2009 Gefitinib, commonly known as Iressa ®, has been used primarily to treat non-small cell lung cancer as well as breast and prostate cancer. ... Mesothelioma.net Blog ASCO Releases Annual Progress Report on Top Cancer Research Advances - Nov 11, 2009 ...specific subset of patients with non-small cell lung cancer ( NSCLC ) who benefit from first-line treatment with the targeted drug gefitinib ( Iressa ). ... Media Newswire (press release) Biotech company's drug shows potential - Nov 9, 2009 A handful of kinase inhibitors have been approved for cancer treatment, including Novartis' Gleevec and Astra- Zeneca's Iressa. Many others are being tested ... Buffalo News Susan G. Komen for the Cure Announces Recipients of 2009 Komen Brinker Award ... - Oct 27, 2009 He is chief investigator of two international neoadjuvant endocrine therapy trials, IMPACT and IRESSA 223 and UK principal investigator for several ... Reuters Innovative analytical technology for higher efficiency - Nov 10, 2009 There are several other approved (oncological) drugs (IRESSA?, GLEEVEC?) or drugs in development, whose effectiveness is dependent on the (non-)presence of ... Scientist Live Darrin M Disley, chairman of Horizon Discovery - Nov 5, 2009 This is big for them as they can potentially predict the clinical outcome of drugs like Iressa (non-small lung cancer target) which ostensibly failed in ... Business Weekly AstraZeneca hands global oncology portfolio to Edelman - Nov 4, 2009 The latest additions to its range are Faslodex and Iressa. The disease areas it specialises in are prostate cancer, breast cancer and lung cancer. ... PRWeek UK Personliga piller kan snart vara här - Nov 9, 2009 För nÃ¥gra Ã¥r sedan tog AstraZeneca fram lungcancermedlet Iressa, tänkt att bli en storsäljare efter mÃ¥nga Ã¥rs kostsamma forskningsstudier. ... Svenska Dagbladet IRESSA--早期肺癌最典型的症状 - Oct 19, 2009 ...一旦有显症候，往往已ç»?接近ä¸æ™šæœŸï¼Œæ¤æ—¶æ²»ç–—å·²ç»?é?žå¸¸æ£˜æ‰‹ï¼Œè€Œä¸”病人的æ»äº¡çŽ‡è¾ƒé«˜ã€‚所以IRESSAæ??醒您:对于肺癌，贵在在其诊æ–ã€?早期治疗。 中金在线 (博客) AstraZeneca investit dans la recherche en France - Oct 24, 2009 L'autre laboratoire est AstraZeneca dont le médicament Iressa commence à être distribué en France, en attendant une autorisation de commercialisation plus ... Le Figaro Редица непроверени лекарÑ?тва Ñ?е разпроÑ?транÑ?ват в СÐ?Щ - Oct 26, 2009 Още по-лош е Ñ?лучаÑ?Ñ‚ Ñ? лекарÑ?твото против рак на белиÑ? дроб Iressa на AstraZaneca. То е одобрено от FDA през 2003 година по бързата процедура и Ñ?поред ... Econ.bg 美 'ì?´ë ˆì‚¬', 'ë¯¸ë“œë¡ ' 등 ê²€ì¦?실패 - Oct 27, 2009 ...ë¯¸êµ FDAê°€ 'ì?´ë ˆì‚¬'(Iressa, gefitinib), 'ë¯¸ë“œë¡ '(midodrine) 등 조기 승ì?¸í•œ ì?˜ì•½í’ˆì?˜ 후ì†? ê²€ì¦?ì—? 실패했다는 지ì ?ì?´ 나왔다. ë¯¸êµ ì •ë¶€ ê°?사ì›?(GAO)ì?€ ë³´ê³ ì„œë¥¼ ... 디지틀보사 Die Macht der Krebsgene - Nov 1, 2009 Wie klein die Gruppe von Patienten werden kann, zeigt die jüngste Zulassung des Lungenkrebsmittels Iressa. Dieses Mittel greift an Wachstumsfaktoren der ... derStandard.at La nanomédecine s'attaque au cancer - Oct 26, 2009 ...les chercheurs ont pu délivrer dans des métastases des médicaments anticancéreux déjà existants (tels que le Gleevec ou l'Iressa) ainsi que des gènes ... Largeur.com Study of lung cancer drug Iressa under way - Mar 4, 2005 WASHINGTON (AP) — A last-chance lung cancer drug that helped patients in preliminary trials didn't do well in a follow-up, a failure that surprised ... USA Today Iressa as Good as Chemotherapy for Lung Cancer - Nov 20, 2008 FRIDAY, Nov. 21 (HealthDay News) -- The cancer-fighting pill Iressa works as well as chemotherapy as a second-line treatment for lung cancer, ... Forbes FDA to limit access to cancer drug Iressa - Jun 17, 2005 WASHINGTON - The government will allow only a few thousand lung cancer patients to continue using a last-chance therapy, after the highly touted Iressa ... msnbc.com Astra's cancer drug Iressa helps Asian non-smokers - Sep 15, 2008 LONDON, Sept 15 (Reuters) - AstraZeneca's cancer drug Iressa should be considered as a first-line therapy for non-smoking Asian patients who develop a ... Forbes … Indication of Iressa (Gefitinib) to Patients Currently Benefiting... - Jun 5, 2006 Iressa received a Notice of Compliance with conditions (NOC/c) on December 17, 2003 for third line therapy of locally advanced or metastatic non-small-cell ... DG News FDA Restricts Access to Cancer Drug, Citing Ineffectiveness - Jun 18, 2005 Iressa was approved in 2003 based on a small trial showing that it shrank tumors in ... Many patients who would have gotten Iressa are now getting Tarceva, ... New York Times AstraZeneca's Iressa matches chemo in lung cancer - Sep 5, 2007 LONDON, Sept 5 (Reuters) - AstraZeneca (AZN.L) said on Wednesday a clinical trial showed its Iressa drug was as effective in treating advanced non-small ... Reuters EDITORIAL:Anti-cancer drug Iressa - Jan 26, 2005 Apanel of experts appointed by the Ministry of Health, Labor and Welfare to re-evaluate the benefits and potential adverse effects of Iressa, a drug used to ... æœ?日新è?ž FDA Limits Use of Lung Cancer Drug Iressa - Jun 21, 2005 By Jennifer Warner. People newly diagnosed with lung cancer should not take the lung cancer drug Iressa, according to new limitations placed on the drug by ... FOXNews Astra files Iressa in EU for selected patients - May 2, 2008 LONDON, May 2 (Reuters) - AstraZeneca Plc (AZN.L) said on Friday it had applied to sell its lung cancer drug Iressa in Europe as a treatment for selected ... Reuters AstraZeneca facing class action suits over Iressa - Feb 3, 2005 ASTRAZENECA'S Japanese subsidiary is facing the threat of a class action lawsuit over the fatal side-effects of Iressa, its lung cancer treatment. ... Times Online Failed lung cancer drug has breast cancer promise - May 15, 2008 Combining Iressa with the breast cancer drug Arimidex helped women ... The surprising findings are the first to show any benefit for Iressa in breast cancer ... Reuters ARCHIVE: Back home looking forward - Oct 31, 2007 I remember Iressa, the pill suggested by Jan's oncologist last August. ... Six months ago, Jan and I were excited when he was offered Iressa. ... Canada.com National Cancer Institute Halts Drug Trial - Apr 19, 2005 The National Cancer Institute (search) said on Monday it halted a trial it was sponsoring of AstraZeneca PLC cancer drug Iressa (search) because the ... FOXNews AstraZeneca moves nearer to scrapping blockbuster drug Iressa. - Jan 5, 2005 Jan. 5--AstraZeneca came a step closer to scrapping Iressa as it withdrew its application to market the drug as a lung cancer treatment in Europe. ... Free with registration - Daily Mail - AccessMyLibrary.com AstraZeneca brings in VCs to boost its $5bn acquisition drive - Oct 8, 2006 The company has already had several setbacks on new drugs this year, including Iressa and Galida. "They are short on products and long on cash," said Mike ... Independent Pill as good as chemo on lung cancer, but costlier - Nov 24, 2008 An international study showed patients on Iressa, an expensive, ... Iressa, made by AstraZeneca PLC, is one of several new targeted drugs that attack ... Jerusalem Post Pazdur's Cancer Rules - Jul 6, 2005 The truth is that Iressa-maker AstraZeneca simply refused to play by Dr. Pazdur's ... Very clearly there are patients whose cancer went away with Iressa. ... Wall Street Journal Studies seek link between estrogen and lung cancer . - May 30, 2006 And some of the newest hing cancer drugs, Tarceva and Iressa, seem to work more often in women. Teasing out the biology behind the gender differences could ... St. Petersburg Times - Google News Archive AstraZeneca's patent application rejected - Nov 21, 2007 Iressa is the third non-Indian drug brand to be turned down under ... Iressa is a branded formulation of the drug, known in generic terms as Gifitinib. ... Livemint AstraZeneca to build $100m research facility in China - May 27, 2006 Two years ago AstraZeneca found that its novel lung cancer drug Iressa did not work on patients in the West but appeared to be of benefit to Asian patients. Independent Tarceva Takes Aim At Cancer - Feb 7, 2005 Tarceva is likely to run ahead of Iressa, a small-molecule EGFR inhibitor ... Because of the disappointing trial, the company will sell Iressa but will no ... Forbes New Hope for a Failed Cancer Drug - Jun 1, 2008 There may be a second life for Iressa, AstraZeneca's once-promising cancer ... Iressa won US Food & Drug Administration approval for lung cancer in 2003 ... BusinessWeek Cancer - The New Frontier: Targeted drugs offer hope of longer... - Nov 20, 2006 She responded to Iressa for 22 months before progression [of cancer]. ... Money aside, Tarceva and Iressa are among the best hopes in a disease whose ... New Zealand Herald Iressa Shows Promise For Treatment Of Metastatic Breast Cancer When … - May 19, 2008 ScienceDaily (May 19, 2008) — Gefitinib, the once-promising drug formerly approved as a second line treatment for lung cancer, also known as Iressa, ... sciencedaily.com FDA Panel Weighs Fate Of a Drug For Cancer - Mar 5, 2005 The case of Iressa has raised questions about whether the FDA's so-called ... Iressa was approved in May 2003 based on small clinical trials without placebo ... New York Times Iressa® (gefitinib) 250 mg Tablets Fail to Demonstrate Non-inferiority... - Oct 11, 2007 OTTAWA, CANADA -- October 11, 2007 -- Health Canada has sent a letter to health care professional involved in the Iressa Patient Registry (IPR), ... DG News Health Canada Endorsed Important Safety Information on Iressa (Gefitin... - Dec 12, 2006 Iressa is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor. Although Iressa is indicated for the treatment of locally advanced non-small ... DG News PILL AS GOOD AS CHEMO ON LUNG CANCER, BUT IT COSTS MORE - Nov 27, 2008 ...[Iressa], made by AstraZeneca PLC, is one of several new targeted drugs that attack ... But Iressa costs thousands of dollars every month, much more than ... Pay-Per-View - South Florida Sun - Sentinel - ProQuest Archiver Drug extends lung cancer patients' survival - Jul 13, 2005 Tarceva costs about $2300 a month; Iressa costs $1800 a month. Another drug, Taxotere, costs $2100 for three weeks. The study's findings could benefit the ... USA Today A Target for Iressa The fall and rise (and fall) of a pharmacogenetics... - Apr 1, 2006 It emerged a seductive idea: Bridging the gap between genetics and pharmacology could allow clinicians to hit cancer cells where it hurts them most. ... Free with registration - The Scientist - AccessMyLibrary.com Brain Tumor - Children Causes - Brain Tumor - Children Health … - Jun 10, 2008 ...determine the treatment course, both for standard chemotherapy and "targeted therapy" biologic drugs, such as gefitinib (Iressa) or erlotinib (Tarceva). ... New York Times New lung cancer drugs show promise - Jul 25, 2005 The government just restricted access to Iressa because it failed to help most patients ... Iressa is made by AstraZeneca PLC; Tarceva is co-marketed by OSI ... msnbc.com New mechanism identified for resistance to targeted lung cancer drugs - Apr 30, 2007 Drugs like Iressa (gefitinib) and Tarceva (erlotinib) are used to treat advanced ... Although treating resistant cell lines with either Iressa or a MET ... webwire.com Predictor of Response to IRESSA(TM) (Gefitinib) Investigated in First... - May 6, 2006 Data announced today at the 42nd American Society of Clinical Oncology (ASCO) Annual Meeting further advanced the understanding of the importance of ... presseportal.de New mechanism identified for resistance to targeted lung cancer drugs - Apr 26, 2007 Drugs like Iressa (gefitinib) and Tarceva (erlotinib) are used to treat advanced ... Although treating resistant cell lines with either Iressa or a MET ... eurekalert.org Test Predicts Response To Cancer Drugs --- Genzyme Launches Method … - Sep 27, 2005 In the case of Iressa, made by AstraZeneca PLC, the drug works only in about 10% of ... This won't help patients in the US get access to Iressa for now. ... Pay-Per-View - Wall Street Journal - Factiva, from Dow Jones Genzyme launches lung-cancer gene test - Dec 4, 2006 ...a marker linked to resistance to certain lung-cancer drugs, including the tyrosine kinase inhibitors Tarceva (erlotinib) and Iressa (gefitinib). ... United Press International New cancer drugs attack along multiple lines - May 14, 2005 These drugs go beyond current favored ones such as Herceptin, Avastin and Iressa, which have impressed scientists for their ability to precisely target ... USA Today ZD1839 (Iressa) for recurrent or metastatic squamous cell carcinoma... - May 1, 2007 Condition Intervention Phase Skin Cancer Drug: Iressa (ZD1839) Phase II Study ID Numbers: ID02-282 ClinicalTrials.gov Identifier: NCT00054691 ... Free with registration - Journal of Drugs in Dermatology - AccessMyLibrary.com BOOST FOR LUNG BATTLE - Jun 22, 2006 Of this group, 80 per cent of people tested by researchers benefited from the drugs, called Iressa and Tarceva. Dr Jeffrey Settleman, a US scientist, ... Scottish Daily Record Determining genetic signature of lung tumours can help guide treatment - May 21, 2008 Iressa, which disables the epidermal growth factor receptor (EGFR) on the ... Iressa treatment continued indefinitely unless significant side effects ... Science Centric Smart drug for lung cancer may be pulled from market - Apr 5, 2005 Two years ago, enormous fanfare greeted the drug, Iressa, which zipped through the ... The Iressa saga also underscores the challenges the FDA and cancer ... Boston Globe Therapy targets brain tumors - Nov 9, 2005 Until now, doctors haven't been able to explain why the drugs Iressa and Tarceva ... Neither Iressa nor Tarceva cures brain cancer, and only 10% to 20% of ... USA Today Cancer Drug Flies Into Turbulence . - Apr 11, 2005 Non-small-cell lung cancer, the type Iressa treats, accounts for about of the ... Iressa, a daily pill that costs more than 1.800 for a month's supply, ... Milwaukee Journal Sentinel - Google News Archive No Relief For AstraZeneca - Jan 31, 2005 17, AstraZeneca Chief Executive Tom McKillop called the news on Iressa a "disappointment" and described 2004 as "a very difficult, challenging year." ... BusinessWeek AstraZeneca to start trials on new lung cancer drug - Jul 5, 2005 Zactima is a once-daily pill that combines the action of Iressa and Tarceva ... AstraZeneca failed to prove last year that Iressa prolongs the life of the ... Independent AstraZeneca needs stronger medicine - Jan 23, 2005 More recently, investors took heart from the potential of such drugs as Crestor, AstraZeneca's anti-cholesterol product, Iressa, a lung cancer treatment, ... Telegraph.co.uk Astra Zeneca withdraws Iressa registration application. - Jan 4, 2005 Astra Zeneca has withdrawn its application to the European pharmaceutical authority EMEA for approval of Iressa for the treatment of patients with non-small ... Pay-Per-View - Dagens Industri - Factiva, from Dow Jones Lift for AZ's anti-cancer drugs - May 17, 2005 AstraZeneca's anti-cancer division was boosted yesterday by promising results from one of the drugs in its pipeline and a glimmer of hope for Iressa, ... guardian.co.uk ZD1839 (Iressa) for recurrent or metastatic squamous cell carcinoma... - Sep 1, 2007 Condition Intervention Phase Skin Cancer Drug: Iressa (ZD1839) Phase II Study ID Numbers: ID02-282 ClinicalTrials.gov Identifier: NCT00054691. Free with registration - Journal of Drugs in Dermatology - AccessMyLibrary.com AstraZeneca cautious despite record profits - Apr 28, 2005 Sales of Iressa were $81 million, supported by an 18 per cent gain in Asia, including China where the drug was launched in February. ... Times Online AstraZeneca expects earnings rise despite Crestor, Exanta, Iressa … - Jan 27, 2005 However, it appears that AZ will become increasingly dependent on older drugs and cost-cutting measures after it failed to prove Iressa extended the life of ... Medical Marketing & Media - Medical Marketing and Media Determining genetic signature of lung tumors can help guide treatment - May 20, 2008 Iressa, which disables the epidermal growth factor receptor (EGFR) on the ... Iressa treatment continued indefinitely unless significant side effects ... eurekalert.org CNN NEWSNIGHT AARON BROWN - Jun 3, 2005 There was one other treatment to try, an experimental drug called IRESSA, ... BROWN: The way IRESSA was supposed to work was unique and also unproven. ... CNN International Exanta returns to haunt Astrazeneca - Feb 23, 2005 The company's third large setback was Iressa, a drug to treat lung cancer which ... Analysts say that though there are still some opportunities for Iressa, ... Telegraph.co.uk Gefitinib (ZD1839, Iressaâ„¢) as palliative treatment in recurrent or … - Oct 10, 2005 To assess the level of activity and toxicity of gefitinib (ZD1839, Iressaâ„¢) in a population of patients with locally recurrent and/or metastatic head and ... Nature.com AstraZeneca Forecasts Run the Gamut - Apr 27, 2005 And the first quarter won't see much revenue from the lung cancer drug Iressa, considering the announcement of test results in December that showed patients ... TheStreet.com - TheStreet.com (subscription) Market Report: Tate & Lyle tumbles on competition concerns - Apr 20, 2005 AstraZeneca added 5p to 2277p as an upgrade from Morgan Stanley offset negative news about the pharma giant's Iressa drug. AZ shares were under pressure at ... Independent AstraZeneca buys biotech KuDOS for £121m - Dec 24, 2005 Cancer is traditionally one of AstraZeneca's strongest areas, but it tripped up last year when newly launched lung cancer pill Iressa failed to boost ... Scotsman New enterprises put doctors on call for investment information - Aug 16, 2005 Natale's access to all the research data on Iressa made him an attractive source for investment researchers seeking inside information. ... New York Times Astrazeneca chief attacks 'unfounded' drug safety scares - Jan 28, 2005 Iressa, the lung cancer drug, has also run into problems. Sir Tom refused to say whether he would waive his bonus. Asked about the new salary scheme for ... Telegraph.co.uk … Detection of EGFR in Blood May Predict Iressa and Tarceva Response... - Jul 12, 2006 Asked whether AstraZeneca, the manufacturer of Iressa, is interested in the possibility that DxS' assay might be a useful tool to guide lung-cancer ... genomeweb.com Iressa Disappointment Is Third Strike for AstraZeneca - Jan 17, 2005 The fortunes appear to have turned for AstraZeneca, which faces yet another blow to its new-product portfolio. New clinical data for its cancer treatment ... ICIS ZD1839 (Iressa[R]) for recurrent or metastatic squamous cell carcinoma... - Jul 1, 2007 Sponsors and Collaborators: MD Anderson Cancer Center and AstraZeneca. The purpose of this study is to explore the activity of ZD1839 administered to ... Free with registration - Journal of Drugs in Dermatology - AccessMyLibrary.com Drug group man who would be king - Mar 15, 2005 Since then, the company has been hit by the US Food & Drug Administration's rejection of anticoagulant pill Exanta, the failure of lung cancer drug Iressa ... Telegraph.co.uk Drug firm lowers sales forecasts - Jan 23, 2005 Astra Zeneca has failed to secure FDA approval for Exanta, a blood-thinning drug, while Iressa, a cancer treatment already available in Japan, ... Times Online ImClone Profit Rose 7% for 2nd Quarter - Jul 27, 2005 Erbitux works by blocking tumor cell growth, providing a targeted therapy much like Genentech's Avastin and AstraZeneca's Iressa. ... New York Times ViroLogic and AstraZeneca to conduct Iressa biomarker study - Mar 7, 2005 ViroLogic announced today that it had entered into an agreement with AstraZeneca to conduct a cancer biomarker study with application to Iressa, ... News-Medical.net AstraZeneca looks to oncology pipeline after failure of Iressa - Jan 20, 2005 AstraZeneca has withdrawn its marketing application for its lung cancer drug Iressa in the European Union following the release of new long-term data which ... Pharmafocus Atlanta health, diet and fitness news | ajc.com - Apr 18, 2005 Iressa was being tested as a lung cancer therapy for those who had failed standard treatments. Its 2003 approval by the US Food and Drug Administration was ... Atlanta Journal Constitution Iressa Doesn't Improve Odds Against Lung Cancer - Oct 27, 2005 THURSDAY, Oct. 27 (HealthDay News) -- The drug Iressa (gefitinib) doesn't significantly improve survival for people with non-small cell lung cancer (NSCLC), ... RedOrbit Astra Zeneca changes Iressa product description. - Jun 18, 2005 Astra Zeneca is changing the product description for its anticancer drug Iressa in America after discussions with the FDA. The new product description ... Pay-Per-View - Dagens Industri - Factiva, from Dow Jones New GE Healthcare has broader reach now . - Apr 4, 2005 They discussed Iressa, and Loescher had GE Healthcare sequence his colleague's ... Iressa. he wasted a year with two treatments that didn't work for him," ... Milwaukee Journal Sentinel - Google News Archive ALSO NOTED: New label for Iressa; Canada rejects Vantas; RegeneRx to … - Jun 16, 2005 ...> AstraZeneca has changed the label on Iressa, restricting its use to patients who have already benefited from the drug or for patients in a clinical trial. ... FierceBiotech Why Some Lung Cancers Stop Responding To Tarceva And Iressa - Feb 25, 2005 ScienceDaily (Feb. 25, 2005) — NEW YORK, February 21, 2005 – Researchers at Memorial Sloan-Kettering Cancer Center (MSKCC) have found an explanation for why ... sciencedaily.com Iressa Has Little Effect on Advanced Breast Cancer: Presented at SABCS - Dec 13, 2005 By Cameron Johnston. SAN ANTONIO, TX -- December 13, 2005 -- Hormone-resistant breast cancers do not appear to respond to treatment with Iressa (gefitinib), ... DG News ZD1839 (Iressa) for recurrent or metastatic squamous cell carcinoma... - Sep 1, 2007 Sponsors and Collaborators: MD Anderson Cancer Center and AstraZeneca. The purpose of this study is to explore the activity of ZD1839 administered to ... $4.95 - Journal of Drugs in Dermatology - ECNext Roche cancer and osteoporosis drugs get EU nod - Jun 28, 2005 Tarceva has already been shown to work better than Iressa and analysts have said the drug could generate annual sales of some $1.6 billion by 2009. ... New Zealand Herald DEAR PHARMACIST SUZY COHEN - Jan 20, 2005 The drug Iressa (gefitinib), which was approved in May 2003 for resistant ... The FDA approved Iressa in a hurry because there appeared to be some survival ... Pay-Per-View - South Florida Sun - Sentinel - ProQuest Archiver Astra Zeneca's Iressa threatened with Japanese ban. - Jan 21, 2005 Astra Zeneca's lung cancer drug Iressa could be banned in Japan after reports that the agent is linked with 588 deaths in that country. ... Pay-Per-View - Dagens Industri - Factiva, from Dow Jones AstraZeneca Takes Cancer Drug Iressa Off Table for New Patients - Jun 27, 2005 AstraZeneca's lung-cancer treatment Iressa will no longer be available to new patients beginning in September under a new labeling plan that will keep the ... Pay-Per-View - Washington Drug Letter - Factiva, from Dow Jones Iressa failure adds to AstraZeneca's woes - Jan 7, 2005 AstraZeneca's troubles continued to add up after the company announced the application withdrawal of Iressa after it failed to show any significant survival ... DrugResearcher.com FDA: gefitinib (Iressa) does not prolong survival.(Brief Article) - Feb 1, 2005 The FDA issued a statement last December urging patients who take gefitinib (Iressa) to consult their physicians, since gefitinib failed to show in a ... Free with registration - Drug Formulary Review - AccessMyLibrary.com Package insert of Iressa to be revised. - Jan 31, 2005 AstraZeneca has been instructed by the PSFB's safety division to revise the package insert for Iressa, an anticancer agent with the active ingredient ... Free with registration - Asia Africa Intelligence Wire - AccessMyLibrary.com … of ovarian cancer patients responsive to Iressa identified, Fox... - Apr 22, 2005 Researchers at Fox Chase Cancer Center in Philadelphia have identified a subset of ovarian cancer patients who appear to respond better than others to ... i-newswire.com Field has big potential . - Oct 3, 2005 ...advantage with Tarceva because it works on a larger percentage of the population' with lung cancer than Iressa. Because of that, the limited Iressa sales, ... Milwaukee Journal Sentinel - Google News Archive … trial of AstraZeneca cancer drug, Iressa - AP Worldstream |... - Apr 18, 2005 National Cancer Institute halts trial of AstraZeneca cancer drug, Iressa ... find AP Worldstream articles. THERESA AGOVINO, AP Business Writer AP ... Pay-Per-View - AP Worldstream - HighBeam Research … Institute halts trial of AstraZeneca cancer drug, Iressa | Article... - Apr 19, 2005 National Cancer Institute halts trial of AstraZeneca cancer drug, Iressa ... find AP Worldstream articles. AP Worldstream 04-19-2005 Dateline: NEW YORK The ... Pay-Per-View - AP Worldstream - HighBeam Research GARDEN STATE BRIEFS - Apr 20, 2005 Gefitinib is manufactured by AstraZeneca under the name Iressa. ... A Genta spokesman said the Genasense results were not specific to Iressa. ... Pay-Per-View - Star-Ledger - Factiva, from Dow Jones Iressa as a Drug for 21st Century Personalized Medicine - Oct 23, 2006 Shoji Kudo, professor of the Department of Pulmonary Medicine, Infection and Oncology, Nippon Medical University, gave a lecture on a large-scale ... Pay-Per-View - Pharma Japan - Factiva, from Dow Jones Chinese Charity Gives Out Free Drugs to Poor Lung Cancer Patients - Jan 25, 2008 The China Charity Federation (CCF) says it will be giving out 27.6 million US dollar worth IRESSA, also called Jifeitini tablets, manufactured by the ... MedIndia IRESSA DECISION TO SET PRECEDENT FOR NEGATIVE FAST-TRACK … - Mar 11, 2005 FDA's handling of the unfavorable clinical trial result from AstraZeneca's cancer drug Iressa will set a precedent for how the agency handles such negative ... Pay-Per-View - FDA Week - Factiva, from Dow Jones New class of drugs may treat lung tumors resistant to Iressa and... - May 11, 2005 A new class of drugs that block the epidermal growth factor receptor (EGFR) on lung cancer cells may get around the growing problem of resistance to ... PsychCentral.com Cancer-drug maker Aveo raises $53M - May 4, 2007 Aveo says its models show that AV-412 is more potent than other EGFR drugs and appears to be active against tumors that are resistant to Tarceva or Iressa. ... VentureBeat ViroLogic and AstraZeneca to Conduct Iressa(R) Biomarker Study - Mar 8, 2005 ViroLogic, Inc (Nasdaq: VLGC) announced today that it had entered into an agreement with AstraZeneca (NYSE: AZN) to conduct a cancer biomarker study with ... Medical News Today - Medical News Today (press release) Targeted Therapy for Non-Small Cell Lung Cancer--An Update from the … - Jul 3, 2005 The Iressa Survival Evaluation in Lung Cancer (ISEL) trial continues to show that ... Iressa was the first EGFR TKI to be approved for the treatment of ... Cancer Consultants Cancer Therapy; Trial: IRESSA failed to significantly prolong... - Jan 25, 2005 2005 JAN 25 - (NewsRx.com & NewsRx.net) -- AstraZeneca announced that the initial analysis of the primary endpoint of Study 709, IRESSA Survival Evaluation ... Pay-Per-View - Cancer Weekly - Factiva, from Dow Jones … Encouraging with Interferon Alpha Plus Iressa (Gefitinib) or... - Nov 22, 2005 By Maggie Schwarz. PHILADELPHIA, PA -- November 22, 2005 -- In a phase 2 study of interferon alpha (IFN) plus either Gleevec (imatinib mesylate) or Iressa ... DG News AstraZeneca shares slump as promotion of Iressa is suspended. - Jan 3, 2005 Anglo-Swedish pharmaceutical major AstraZeneca saw its share price slump on December 17, after the company announced that clinical trials with its lung ... $4.95 - Pharma Marketletter - ECNext |
|
Health Home | Conditions | Cancer | Medications | Surgery | Vaccines The Cancer News Network
COPYRIGHT 2009 CANCERNEWSNETWORK | Privacy |